<DOC>
	<DOCNO>NCT02010775</DOCNO>
	<brief_summary>This study evaluate safety efficacy range dose botulinum toxin Type A ( BOTOX® ) treatment patient bilateral Masseter Muscle Hypertrophy ( MMH ) .</brief_summary>
	<brief_title>Botulinum Toxin Type A ( BOTOX® ) Treatment Masseter Muscle Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Participants Masseter Muscle Hypertrophy Diagnosis Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , condition might interfere neuromuscular function Prior botulinum toxin treatment serotype masseter muscle low face History dental surgical procedure lower facial shape masseter muscle reduction History current temporomandibular joint disorder ( TMJD ) Class III malocclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>